Merck on the Defensive as Lawsuit Emerges to Halt Keytruda's New Version Launch
2 days ago
In a significant legal development, pharmaceutical giant Merck is confronting a lawsuit filed by a competitor that aims to impede the upcoming release of a more user-friendly formulation of its renowned cancer immunotherapy, Keytruda. This new version has been optimized for easier administration, raising competitive stakes in an already fiercely contested market.
Continue reading
Merck Plans to Launch New Version of Keytruda Cancer Drug by 2025
3 months ago
In a significant turnaround in the oncology drug landscape, Merck & Co. has announced plans to launch a simplified version of its leading cancer immunotherapy drug, Keytruda, by the year 2025. This move is anticipated to enhance accessibility for patients and streamline treatment regimens, making it a noteworthy development in cancer care.
Continue reading